Arcturus Therapeutics (ARCT) Competitors $17.77 +0.85 (+5.02%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$17.73 -0.04 (-0.23%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends ARCT vs. TARS, JANX, AGIO, NAMS, IDYA, SDGR, TVTX, BLTE, VERA, and IOVAShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Tarsus Pharmaceuticals Janux Therapeutics Agios Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Schrödinger Travere Therapeutics Belite Bio Vera Therapeutics Iovance Biotherapeutics Arcturus Therapeutics (NASDAQ:ARCT) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Do institutionals and insiders believe in ARCT or TARS? 94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to ARCT or TARS? In the previous week, Arcturus Therapeutics had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.87 beat Arcturus Therapeutics' score of 0.55 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ARCT or TARS? Arcturus Therapeutics has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$169.93M2.83-$29.73M-$2.22-8.00Tarsus Pharmaceuticals$129.62M14.11-$135.89M-$3.81-12.56 Which has more risk & volatility, ARCT or TARS? Arcturus Therapeutics has a beta of 2.62, meaning that its stock price is 162% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Do analysts rate ARCT or TARS? Arcturus Therapeutics presently has a consensus price target of $65.00, indicating a potential upside of 265.79%. Tarsus Pharmaceuticals has a consensus price target of $56.00, indicating a potential upside of 17.06%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ARCT or TARS more profitable? Arcturus Therapeutics has a net margin of -36.39% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Arcturus Therapeutics' return on equity of -22.39% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-36.39% -22.39% -14.81% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Does the MarketBeat Community believe in ARCT or TARS? Arcturus Therapeutics received 394 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 66.67% of users gave Tarsus Pharmaceuticals an outperform vote while only 66.17% of users gave Arcturus Therapeutics an outperform vote. CompanyUnderperformOutperformArcturus TherapeuticsOutperform Votes44266.17% Underperform Votes22633.83% Tarsus PharmaceuticalsOutperform Votes4866.67% Underperform Votes2433.33% SummaryArcturus Therapeutics beats Tarsus Pharmaceuticals on 15 of the 18 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$481.39M$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-8.006.1326.4618.82Price / Sales2.83311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book1.716.747.634.64Net Income-$29.73M$138.11M$3.18B$245.69M7 Day Performance-1.55%-2.43%-1.91%-2.66%1 Month Performance6.15%-1.91%-0.19%-2.15%1 Year Performance-52.54%-5.03%16.70%12.90% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.6171 of 5 stars$17.77+5.0%$65.00+265.8%-49.6%$481.39M$169.93M-8.00180TARSTarsus Pharmaceuticals1.4247 of 5 stars$50.22-3.8%$56.00+11.5%+58.8%$1.92B$17.45M-13.1850Gap UpJANXJanux Therapeutics3.1282 of 5 stars$36.37-2.2%$89.90+147.2%+174.0%$1.91B$13.05M-31.0930AGIOAgios Pharmaceuticals4.3439 of 5 stars$33.22-0.2%$56.33+69.6%+31.4%$1.89B$26.82M2.92390Earnings ReportShort Interest ↓NAMSNewAmsterdam Pharma3.2893 of 5 stars$19.91+2.6%$41.60+108.9%-13.9%$1.84B$14.09M0.004Upcoming EarningsIDYAIDEAYA Biosciences3.8329 of 5 stars$21.00+1.2%$53.58+155.2%-50.9%$1.82B$23.39M-9.0180Gap UpSDGRSchrödinger1.816 of 5 stars$24.85+1.7%$32.11+29.2%-24.6%$1.81B$216.67M-10.62790Upcoming EarningsPositive NewsTVTXTravere Therapeutics2.9598 of 5 stars$22.91-3.4%$27.77+21.2%+178.9%$1.79B$145.24M-5.04460Earnings ReportAnalyst ForecastNews CoverageGap DownBLTEBelite Bio3.2124 of 5 stars$56.00-1.0%$96.33+72.0%+26.3%$1.78BN/A-50.4510Positive NewsVERAVera Therapeutics2.2698 of 5 stars$27.46-19.7%$65.44+138.3%-35.8%$1.74BN/A-10.5240High Trading VolumeIOVAIovance Biotherapeutics4.0357 of 5 stars$5.57+4.3%$22.69+307.3%-63.3%$1.70B$1.19M-3.74500 Related Companies and Tools Related Companies Tarsus Pharmaceuticals Alternatives Janux Therapeutics Alternatives Agios Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives IDEAYA Biosciences Alternatives Schrödinger Alternatives Travere Therapeutics Alternatives Belite Bio Alternatives Vera Therapeutics Alternatives Iovance Biotherapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARCT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts